Healthcare provider profile · identity verified

Nathalee Kong, MD

Internal Medicine · BOSTON, MA · NPI 1699113241

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	300	95
Omeprazole	Omeprazole	212	63
Amlodipine Besylate	Amlodipine Besylate	160	49
Losartan Potassium	Losartan Potassium	146	43
Lisinopril	Lisinopril	135	46
Oxycodone Hcl	Oxycodone Hcl	129	17
Metoprolol Succinate	Metoprolol Succinate	126	39
Levothyroxine Sodium	Levothyroxine Sodium	107	31
Metformin Hcl	Metformin Hcl	90	32
Simvastatin	Simvastatin	87	21
Irbesartan	Irbesartan	83	26
Eliquis	Apixaban	70	15
Gabapentin	Gabapentin	62	18
Allopurinol	Allopurinol	61	14
Famotidine	Famotidine	59	13
Albuterol Sulfate Hfa	Albuterol Sulfate	57	23
Tramadol Hcl	Tramadol Hcl	57	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	55	13
Methadone Hcl	Methadone Hcl	54	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	52	15
Lorazepam	Lorazepam	52	17
Duloxetine Hcl	Duloxetine Hcl	49	suppressed
Jardiance	Empagliflozin	47	15
Labetalol Hcl	Labetalol Hcl	47	14
Ozempic	Semaglutide	47	13
Ibuprofen	Ibuprofen	39	20
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	38	suppressed
Mirtazapine	Mirtazapine	37	suppressed
Trazodone Hcl	Trazodone Hcl	37	14
Citalopram Hbr	Citalopram Hydrobromide	34	suppressed
Trulicity	Dulaglutide	33	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	32	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	32	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	31	11
Ventolin Hfa	Albuterol Sulfate	31	11
Furosemide	Furosemide	30	11
Metformin Hcl Er	Metformin Hcl	29	11
Potassium Chloride	Potassium Chloride	29	suppressed
Buprenorphine-Naloxone	Buprenorphine Hcl/Naloxone Hcl	27	suppressed
Clonazepam	Clonazepam	27	suppressed
Ezetimibe	Ezetimibe	27	suppressed
Alendronate Sodium	Alendronate Sodium	25	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	25	suppressed
Pravastatin Sodium	Pravastatin Sodium	25	suppressed
Sertraline Hcl	Sertraline Hcl	25	12
Sumatriptan Succinate	Sumatriptan Succinate	25	suppressed
Loperamide	Loperamide Hcl	22	suppressed
Doxepin Hcl	Doxepin Hcl	21	suppressed
Nifedipine Er	Nifedipine	21	suppressed
Amoxicillin	Amoxicillin	20	suppressed
Atenolol	Atenolol	20	suppressed
Fluticasone Propionate	Fluticasone Propionate	20	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	20	suppressed
Valsartan	Valsartan	19	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	18	suppressed
Montelukast Sodium	Montelukast Sodium	17	suppressed
Pregabalin	Pregabalin	17	suppressed
Spironolactone	Spironolactone	17	suppressed
Bupropion Hcl Sr	Bupropion Hcl	16	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	16	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	16	11
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	16	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	15	suppressed
Synthroid	Levothyroxine Sodium	15	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	15	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	14	suppressed
Baclofen	Baclofen	14	suppressed
Diclofenac Sodium	Diclofenac Sodium	14	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	14	suppressed
Ondansetron Odt	Ondansetron	14	suppressed
Bumetanide	Bumetanide	13	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	13	suppressed
Oxycontin	Oxycodone Hcl	13	suppressed
Tizanidine Hcl	Tizanidine Hcl	13	suppressed
Acyclovir	Acyclovir	12	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	12	suppressed
Naproxen	Naproxen	12	suppressed
Torsemide	Torsemide	12	suppressed
Xarelto	Rivaroxaban	12	suppressed
Carvedilol	Carvedilol	11	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	11	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	11	suppressed
Warfarin Sodium	Warfarin Sodium	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error